AI Analysis AI Analysis of GMAB
AI-Powered Market Insights
Stock Analysis PRO New!
Risk Assessment
Trading Strategy
PDF

Green day on Monday for Genmab A/S stock after gaining 0.529%
(Updated on Nov 17, 2025)

SIGN UP FREE
or
Creating an account or logging in means you agree to StockInvest.us Terms of Use and Privacy Policy.
Sell candidate since Nov 10, 2025 Gain 4.68%

The Genmab A/S stock price gained 0.529% on the last trading day (Monday, 17th Nov 2025), rising from $30.26 to $30.42. During the last trading day the stock fluctuated 2.03% from a day low at $30.28 to a day high of $30.90. The price has risen in 7 of the last 10 days and is up by 5.96% over the past 2 weeks. Volume fell on the last day by -542 thousand shares and in total, 883 thousand shares were bought and sold for approximately $26.86 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

The stock lies in the lower part of a wide and strong rising trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $29.20 is broken, it will firstly indicate a slower rate of rising, but may also be an early warning for a trend shift. Given the current short-term trend, the stock is expected to rise 18.90% during the next 3 months and, with a 90% probability hold a price between $34.72 and $43.23 at the end of this 3-month period.

GMAB Signals & Forecast

There are mixed signals in the stock today. The Genmab A/S stock holds a buy signal from the short-term Moving Average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term Moving Average at $30.69. On a fall, the stock will find some support from the short-term average at $29.92. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. A sell signal was issued from a pivot top point on Friday, October 03, 2025, and so far it has fallen -9.36%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell during the last trading day despite gaining prices. This causes a divergence between volume and price and it may be an early warning. The stock should be watched closely.

Support, Risk & Stop-loss for Genmab A/S stock

Genmab A/S finds support from accumulated volume at $29.89 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock is usually traded at a good volume, and with minor daily changes, the risk is considered to be low. During the last day, the stock moved $0.615 (2.03%) between high and low. For the last week, the stock has had daily average volatility of 2.12%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (GMAB) For The Upcoming Trading Day Of Tuesday 18th

For the upcoming trading day on Tuesday, 18th we expect Genmab A/S to open at $30.53, and during the day (based on 14 day Average True Range), to move between $30.04 and $30.80, which gives a possible trading interval of +/-$0.754 (+/-2.51%) up or down from last closing price. If Genmab A/S takes out the full calculated possible swing range there will be an estimated 2.51% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $30.67 (0.82%) than the support at $29.89 (1.74%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is Genmab A/S stock A Buy?

Genmab A/S holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

Current score: -3.123 Sell Candidate Unchanged

Predicted Fair Opening Price

Predicted fair opening price on November 18, 2025 - $30.53 ( 0.367%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker*
*Your capital is at risk

GMAB Performance

Trading levels for GMAB

Full Access. No Commitment. 14 Days Free!
Long & Short-Term Golden Star Lists
AI Stock Analysis*
Top 5 Candidates on Every List
Premium Lists
Ad-FREE Browsing
Advanced Stock Screener

Fibonacci Support & Resistance Levels

Level Price
R3 31.15 2.39%
R2 30.91 1.62%
R1 30.77 1.14%
Price 30.42
S1 30.30 -0.405%
S2 30.15 -0.88%
S3 29.92 -1.65%

Accumulated Volume Support & Resistance Levels

Level Price
R3 33.31 9.50%
R2 32.75 7.66%
R1 30.67 0.82%
Price 30.42
S1 29.89 -1.74%
S2 29.33 -3.58%
S3 28.84 -5.19%

FAQ

What is the symbol for Genmab A/S Stock and on which exchange is it traded?
The symbol for Genmab A/S is GMAB and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Genmab A/S Stock?
Genmab A/S holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

How to buy Genmab A/S Stock?
Genmab A/S Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Genmab A/S Stock.

What's the current price of Genmab A/S Stock?
As of the end of day on the Nov 17, 2025, the price of an Genmab A/S (GMAB) share was $30.42.

What is the 52-week high and low for Genmab A/S Stock?
The 52-week high for Genmab A/S Stock is $33.65 and the 52-week low is $17.24.

What is the market capitalization of Genmab A/S Stock?
As of the Nov 17, 2025, the market capitalization of Genmab A/S is 18.729B.

When is the next earnings date for Genmab A/S?
The upcoming earnings date for Genmab A/S is Feb 11, 2026.
Click to get the best stock tips daily for free!
ABOUT GENMAB A/S
Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esoph...
GOLDEN STAR
Ticker Change Signal Date
UNIT
$6.00
4.83% Nov 04
TBPH
$14.14
27.58% Oct 23
A
AMIX
$1.12
2.68% Oct 23
COCO
$40.85
11.21% Oct 23
LAUR
$29.55
1.20% Oct 22

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE